A phase 3 clinical study of HTU-520 in patients with onychomycosis.
Phase 3
- Conditions
- Onychomycosis
- Registration Number
- JPRN-jRCT2080221109
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with involvement of nail
- Patients who were found to have dermatophytosis of nail by direct microscopy
- Patients in whom the dermatophyte infection of nail was identified
Exclusion Criteria
- Patients who used oral or injectable antifungal drugs within 36 weeks before informed consent was obtained
- Patients who used topical antifungal drugs on the area to be examined or the surrounding area up to the distal joint within 4 weeks before informed consent was obtained
- Patients who used terbinafine hydrochloride-containing topical antifungal drugs within 12 weeks before informed consent was obtained
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy
- Secondary Outcome Measures
Name Time Method Safety